Search Results

You are looking at 1 - 8 of 8 items for :

  • "galactomannan" x
Clear All
Full access

Johan Maertens, Kristel Buvé and Elias Anaissie

-emptive antifungal therapy: still a way to go . Curr Opin Infect Dis 2006 ; 19 : 551 – 556 . 10. Mennink-Kersten MA Donnelly JP Verweij PE . Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis . Lancet

Full access

Maxim Norkin and John R. Wingard

of the limitations of microbiologic techniques, noncultural methods such as galactomannan (GM) antigen; β-(1-3)-D-glucan (BDG) antigen; and PCR-based assays have been introduced, 5 , 27 - 29 and the serum GM (Platelia Aspergillus, Bio

Full access

Antonio V. Gonzalez, Andrew J. Ullmann, Nikolaos G. Almyroudis and Brahm H. Segal

. 9. Wheat LJ . Rapid diagnosis of invasive aspergillosis by antigen detection . Transpl Infect Dis 2003 ; 5 : 158 – 166 . 10. Mennink-Kersten MA Donnelly JP Verweij PE . Detection of circulating galactomannan for the diagnosis and

Full access

Thomas A. Cumbo and Brahm H. Segal

. The contribution of CT to early diagnosis and aggressive management . Chest 1987 ; 92 : 95 – 99 . 39 Bretagne S Costa JM Bart-Delabesse E . Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for

Full access

Samuel L. Aitken, Jerod L. Nagel, Lilian Abbo, William Alegria, Jason N. Barreto, Sanjeet Dadwal, Alison G. Freifeld, Rupali Jain, Steven A. Pergam, Frank P. Tverdek, Susan K. Seo and on behalf of the Antimicrobial Stewardship in Cancer Consortium ASCC

. Rapid diagnostics (eg, T2Candida), biomarkers (eg, galactomannan, 1-3-beta- d -glucan), and improved imaging may increase the ability to rapidly diagnose and treat true fungal infections, provide targeted therapy while minimizing empirical therapy, and

Full access

-45. Clinical Value of the Combining Detection of Galactomannan Test and CT Findings for Diagnosis of Invasive Pulmonary Aspergillosis Li Gao, MD From Peking University First Hospital, China Objective: This study analyzed the diagnostic value of specific

Full access

Lindsey Robert Baden, Sankar Swaminathan, Michael Angarone, Gayle Blouin, Bernard C. Camins, Corey Casper, Brenda Cooper, Erik R. Dubberke, Ashley Morris Engemann, Alison G. Freifeld, John N. Greene, James I. Ito, Daniel R. Kaul, Mark E. Lustberg, Jose G. Montoya, Ken Rolston, Gowri Satyanarayana, Brahm Segal, Susan K. Seo, Shmuel Shoham, Randy Taplitz, Jeffrey Topal, John W. Wilson, Karin G. Hoffmann and Courtney Smith

Prophylaxis with voriconazole was compared with fluconazole in a large randomized double-blind study that included serum galactomannan surveillance in allogeneic HCT recipients (N=600). 24 Patients were randomized to receive the study drugs for 100 or 180

Full access

Lindsey Robert Baden, William Bensinger, Michael Angarone, Corey Casper, Erik R. Dubberke, Alison G. Freifeld, Ramiro Garzon, John N. Greene, John P. Greer, James I. Ito, Judith E. Karp, Daniel R. Kaul, Earl King, Emily Mackler, Kieren A. Marr, Jose G. Montoya, Ashley Morris-Engemann, Peter G. Pappas, Ken Rolston, Brahm Segal, Susan K. Seo, Sankar Swaminathan, Maoko Naganuma and Dorothy A. Shead

Prophylaxis with voriconazole was compared with fluconazole in a large, randomized, double-blind study that included serum galactomannan surveillance in allogeneic HSCT recipients (N=600). 114 No difference was noted in the primary end point (invasive fungal